Compare · ALMR vs RVTY
ALMR vs RVTY
Side-by-side comparison of Alamar Biosciences Inc. (ALMR) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALMR and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $17.26B, about 9.1x ALMR ($1.90B).
- Both names hit the wire about 7 times in the past 4 weeks.
- RVTY has more recent analyst coverage (23 ratings vs 5 for ALMR).
- Company
- Alamar Biosciences Inc.
- Revvity Inc.
- Price
- $25.36-7.16%
- $152.62-1.34%
- Market cap
- $1.90B
- $17.26B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 7
- 7
- Recent ratings
- 5
- 23
Latest ALMR
- SEC Form 144 filed by Alamar Biosciences Inc.
- SEC Form 144 filed by Alamar Biosciences Inc.
- SEC Form 144 filed by Alamar Biosciences Inc.
- SEC Form 144 filed by Alamar Biosciences Inc.
- Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026
- Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
- Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment
- General Counsel Brottem John L. was granted 29,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Brottem John L.
- Director Ragusa Robert P was granted 5,686 shares (SEC Form 4)
Latest RVTY
- Revvity to Present at Upcoming Investor Conferences
- William Blair initiated coverage on Revvity
- Revvity to Host Investor Day
- VP and CAO Gonzales Anita sold $13,060 worth of shares (84 units at $155.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)
- Revvity to Hold Earnings Call on November 3, 2026
- Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
- Officer Krakowiak Maxwell sold $235,728 worth of shares (1,631 units at $144.53) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 14,781 units (SEC Form 4)
- Officer Vohra Tajinder S sold $1,032,650 worth of shares (7,330 units at $140.88) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 6,635 units (SEC Form 4)
- UBS resumed coverage on Revvity with a new price target
- Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery